nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ABCB1—peripheral nervous system neoplasm	0.269	1	CbGaD
Fluoxetine—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0497	0.114	CbGbCtD
Fluoxetine—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0392	0.0898	CbGbCtD
Fluoxetine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0313	0.0719	CbGbCtD
Fluoxetine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0274	0.0629	CbGbCtD
Fluoxetine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0274	0.0629	CbGbCtD
Fluoxetine—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0263	0.0602	CbGbCtD
Fluoxetine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0251	0.0575	CbGbCtD
Fluoxetine—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0213	0.0488	CbGbCtD
Fluoxetine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.019	0.0436	CbGbCtD
Fluoxetine—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.018	0.0412	CbGbCtD
Fluoxetine—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0165	0.0378	CbGbCtD
Fluoxetine—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0164	0.0377	CbGbCtD
Fluoxetine—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0153	0.035	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.0143	0.0327	CbGbCtD
Fluoxetine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0123	0.0281	CbGbCtD
Fluoxetine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0117	0.0268	CbGbCtD
Fluoxetine—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0112	0.0258	CbGbCtD
Fluoxetine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0109	0.025	CbGbCtD
Fluoxetine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0107	0.0246	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00731	0.0168	CbGbCtD
Fluoxetine—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00701	0.0161	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00689	0.0158	CbGbCtD
Fluoxetine—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00642	0.0147	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00438	0.0101	CbGbCtD
Fluoxetine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0035	0.234	CbGeAlD
Fluoxetine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00128	0.0855	CbGeAlD
Fluoxetine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.0012	0.08	CbGeAlD
Fluoxetine—HTR2C—ganglion—peripheral nervous system neoplasm	0.000921	0.0615	CbGeAlD
Fluoxetine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.000912	0.0609	CbGeAlD
Fluoxetine—HTR2A—pons—peripheral nervous system neoplasm	0.000902	0.0602	CbGeAlD
Fluoxetine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.000873	0.0583	CbGeAlD
Fluoxetine—SLC6A2—nerve—peripheral nervous system neoplasm	0.000778	0.0519	CbGeAlD
Fluoxetine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.000768	0.0513	CbGeAlD
Fluoxetine—HTR2A—nerve—peripheral nervous system neoplasm	0.000468	0.0312	CbGeAlD
Fluoxetine—HTR2A—ganglion—peripheral nervous system neoplasm	0.000462	0.0308	CbGeAlD
Fluoxetine—SIGMAR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000426	0.0284	CbGeAlD
Fluoxetine—SIGMAR1—parotid gland—peripheral nervous system neoplasm	0.000402	0.0268	CbGeAlD
Fluoxetine—HTR2C—brainstem—peripheral nervous system neoplasm	0.0004	0.0267	CbGeAlD
Fluoxetine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.000379	0.0253	CbGeAlD
Fluoxetine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.000334	0.0223	CbGeAlD
Fluoxetine—HTR2A—brainstem—peripheral nervous system neoplasm	0.000201	0.0134	CbGeAlD
Fluoxetine—SIGMAR1—cerebellum—peripheral nervous system neoplasm	0.000186	0.0124	CbGeAlD
Fluoxetine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000183	0.0122	CbGeAlD
Fluoxetine—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000149	0.00992	CbGeAlD
Fluoxetine—HTR2A—cerebellum—peripheral nervous system neoplasm	9.9e-05	0.00661	CbGeAlD
Fluoxetine—CYP2D6—cerebellum—peripheral nervous system neoplasm	9.02e-05	0.00602	CbGeAlD
Fluoxetine—ABCB1—cerebellum—peripheral nervous system neoplasm	6.48e-05	0.00433	CbGeAlD
Fluoxetine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000209	CcSEcCtD
Fluoxetine—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	5.82e-05	0.000208	CcSEcCtD
Fluoxetine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	5.81e-05	0.000208	CcSEcCtD
Fluoxetine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	5.79e-05	0.000207	CcSEcCtD
Fluoxetine—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000206	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	5.75e-05	0.000206	CcSEcCtD
Fluoxetine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	5.75e-05	0.000206	CcSEcCtD
Fluoxetine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	5.74e-05	0.000205	CcSEcCtD
Fluoxetine—Weight increased—Epirubicin—peripheral nervous system neoplasm	5.74e-05	0.000205	CcSEcCtD
Fluoxetine—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000204	CcSEcCtD
Fluoxetine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	5.7e-05	0.000204	CcSEcCtD
Fluoxetine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	5.7e-05	0.000204	CcSEcCtD
Fluoxetine—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000203	CcSEcCtD
Fluoxetine—Somnolence—Etoposide—peripheral nervous system neoplasm	5.68e-05	0.000203	CcSEcCtD
Fluoxetine—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	5.68e-05	0.000203	CcSEcCtD
Fluoxetine—Asthenia—Vincristine—peripheral nervous system neoplasm	5.66e-05	0.000203	CcSEcCtD
Fluoxetine—Pneumonia—Epirubicin—peripheral nervous system neoplasm	5.65e-05	0.000202	CcSEcCtD
Fluoxetine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000201	CcSEcCtD
Fluoxetine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	5.62e-05	0.000201	CcSEcCtD
Fluoxetine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	5.61e-05	0.000201	CcSEcCtD
Fluoxetine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	5.6e-05	0.0002	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000199	CcSEcCtD
Fluoxetine—Rash—Dactinomycin—peripheral nervous system neoplasm	5.57e-05	0.000199	CcSEcCtD
Fluoxetine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	5.56e-05	0.000199	CcSEcCtD
Fluoxetine—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000198	CcSEcCtD
Fluoxetine—Renal failure—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000198	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	5.52e-05	0.000197	CcSEcCtD
Fluoxetine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	5.52e-05	0.000197	CcSEcCtD
Fluoxetine—Fatigue—Etoposide—peripheral nervous system neoplasm	5.51e-05	0.000197	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	5.51e-05	0.000197	CcSEcCtD
Fluoxetine—Stomatitis—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000196	CcSEcCtD
Fluoxetine—Jaundice—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000196	CcSEcCtD
Fluoxetine—Constipation—Etoposide—peripheral nervous system neoplasm	5.47e-05	0.000196	CcSEcCtD
Fluoxetine—Pain—Etoposide—peripheral nervous system neoplasm	5.47e-05	0.000196	CcSEcCtD
Fluoxetine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000195	CcSEcCtD
Fluoxetine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000195	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000195	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	5.42e-05	0.000194	CcSEcCtD
Fluoxetine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.42e-05	0.000194	CcSEcCtD
Fluoxetine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.4e-05	0.000193	CcSEcCtD
Fluoxetine—Sweating—Epirubicin—peripheral nervous system neoplasm	5.39e-05	0.000193	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.39e-05	0.000193	CcSEcCtD
Fluoxetine—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000192	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.32e-05	0.00019	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.31e-05	0.00019	CcSEcCtD
Fluoxetine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.3e-05	0.00019	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.28e-05	0.000189	CcSEcCtD
Fluoxetine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.000189	CcSEcCtD
Fluoxetine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.27e-05	0.000188	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.000188	CcSEcCtD
Fluoxetine—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.25e-05	0.000188	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.23e-05	0.000187	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.23e-05	0.000187	CcSEcCtD
Fluoxetine—Dizziness—Vincristine—peripheral nervous system neoplasm	5.22e-05	0.000187	CcSEcCtD
Fluoxetine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.21e-05	0.000186	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000186	CcSEcCtD
Fluoxetine—Rash—Alitretinoin—peripheral nervous system neoplasm	5.16e-05	0.000185	CcSEcCtD
Fluoxetine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.16e-05	0.000185	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000184	CcSEcCtD
Fluoxetine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.14e-05	0.000184	CcSEcCtD
Fluoxetine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000184	CcSEcCtD
Fluoxetine—Headache—Alitretinoin—peripheral nervous system neoplasm	5.13e-05	0.000184	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000183	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.1e-05	0.000182	CcSEcCtD
Fluoxetine—Urticaria—Etoposide—peripheral nervous system neoplasm	5.08e-05	0.000182	CcSEcCtD
Fluoxetine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000181	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000181	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000181	CcSEcCtD
Fluoxetine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000181	CcSEcCtD
Fluoxetine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.05e-05	0.000181	CcSEcCtD
Fluoxetine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.05e-05	0.000181	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000181	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000181	CcSEcCtD
Fluoxetine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.00018	CcSEcCtD
Fluoxetine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.00018	CcSEcCtD
Fluoxetine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.00018	CcSEcCtD
Fluoxetine—Vomiting—Vincristine—peripheral nervous system neoplasm	5.02e-05	0.000179	CcSEcCtD
Fluoxetine—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.01e-05	0.000179	CcSEcCtD
Fluoxetine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.01e-05	0.000179	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.000178	CcSEcCtD
Fluoxetine—Rash—Vincristine—peripheral nervous system neoplasm	4.98e-05	0.000178	CcSEcCtD
Fluoxetine—Dermatitis—Vincristine—peripheral nervous system neoplasm	4.97e-05	0.000178	CcSEcCtD
Fluoxetine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	4.97e-05	0.000178	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000177	CcSEcCtD
Fluoxetine—Headache—Vincristine—peripheral nervous system neoplasm	4.94e-05	0.000177	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000175	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.88e-05	0.000174	CcSEcCtD
Fluoxetine—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.86e-05	0.000174	CcSEcCtD
Fluoxetine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.86e-05	0.000174	CcSEcCtD
Fluoxetine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.77e-05	0.000171	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.77e-05	0.000171	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.00017	CcSEcCtD
Fluoxetine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.71e-05	0.000168	CcSEcCtD
Fluoxetine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.000168	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000168	CcSEcCtD
Fluoxetine—Nausea—Vincristine—peripheral nervous system neoplasm	4.69e-05	0.000168	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000167	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.000167	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.000167	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	4.64e-05	0.000166	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000166	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000164	CcSEcCtD
Fluoxetine—Asthenia—Etoposide—peripheral nervous system neoplasm	4.59e-05	0.000164	CcSEcCtD
Fluoxetine—Chills—Epirubicin—peripheral nervous system neoplasm	4.53e-05	0.000162	CcSEcCtD
Fluoxetine—Pruritus—Etoposide—peripheral nervous system neoplasm	4.52e-05	0.000162	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	4.51e-05	0.000161	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.000161	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—peripheral nervous system neoplasm	4.46e-05	0.000159	CcSEcCtD
Fluoxetine—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.44e-05	0.000159	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000158	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	4.41e-05	0.000158	CcSEcCtD
Fluoxetine—Rash—Cisplatin—peripheral nervous system neoplasm	4.4e-05	0.000157	CcSEcCtD
Fluoxetine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.4e-05	0.000157	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000157	CcSEcCtD
Fluoxetine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.37e-05	0.000156	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000156	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000155	CcSEcCtD
Fluoxetine—Tension—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000154	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000154	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000153	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000152	CcSEcCtD
Fluoxetine—Dizziness—Etoposide—peripheral nervous system neoplasm	4.23e-05	0.000151	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000151	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—peripheral nervous system neoplasm	4.19e-05	0.00015	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000149	CcSEcCtD
Fluoxetine—Nausea—Cisplatin—peripheral nervous system neoplasm	4.15e-05	0.000148	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000148	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000146	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.000146	CcSEcCtD
Fluoxetine—Vomiting—Etoposide—peripheral nervous system neoplasm	4.06e-05	0.000145	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000145	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000145	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—peripheral nervous system neoplasm	4.04e-05	0.000144	CcSEcCtD
Fluoxetine—Rash—Etoposide—peripheral nervous system neoplasm	4.03e-05	0.000144	CcSEcCtD
Fluoxetine—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.03e-05	0.000144	CcSEcCtD
Fluoxetine—Headache—Etoposide—peripheral nervous system neoplasm	4.01e-05	0.000143	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4e-05	0.000143	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000143	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000142	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000142	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000141	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000141	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000141	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000141	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000141	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.00014	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000139	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000138	CcSEcCtD
Fluoxetine—Cough—Epirubicin—peripheral nervous system neoplasm	3.83e-05	0.000137	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000136	CcSEcCtD
Fluoxetine—Nausea—Etoposide—peripheral nervous system neoplasm	3.8e-05	0.000136	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.79e-05	0.000136	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000135	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000134	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000134	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000134	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000134	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000134	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000133	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.000133	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000132	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000131	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.66e-05	0.000131	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000131	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.00013	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.00013	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000129	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000128	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000128	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000128	CcSEcCtD
Fluoxetine—Infection—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.000127	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000127	CcSEcCtD
Fluoxetine—Shock—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000126	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000126	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000125	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.000125	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000125	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000124	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000124	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.000124	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.000124	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.000124	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000123	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000123	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000122	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000122	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000121	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.00012	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.00012	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000119	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000118	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000117	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000117	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000116	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.24e-05	0.000116	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000116	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000115	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000115	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000115	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000114	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000114	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000113	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000113	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000111	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000111	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000111	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000111	CcSEcCtD
Fluoxetine—Pain—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.00011	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.00011	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000108	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000107	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000106	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000106	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.95e-05	0.000106	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000105	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.93e-05	0.000105	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	0.000104	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.88e-05	0.000103	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	0.000102	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	0.000102	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.85e-05	0.000102	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.000101	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.000101	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000101	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000101	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.73e-05	9.77e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	9.7e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.64e-05	9.44e-05	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	9.42e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	9.38e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	9.38e-05	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.57e-05	9.2e-05	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.54e-05	9.07e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.45e-05	8.77e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	8.74e-05	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.38e-05	8.51e-05	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.37e-05	8.48e-05	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.35e-05	8.39e-05	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.28e-05	8.15e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	8.11e-05	CcSEcCtD
Fluoxetine—Rash—Epirubicin—peripheral nervous system neoplasm	2.26e-05	8.08e-05	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.26e-05	8.07e-05	CcSEcCtD
Fluoxetine—Headache—Epirubicin—peripheral nervous system neoplasm	2.25e-05	8.03e-05	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.19e-05	7.84e-05	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—peripheral nervous system neoplasm	2.13e-05	7.61e-05	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	7.54e-05	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.48e-05	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.47e-05	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	7.43e-05	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.97e-05	7.04e-05	CcSEcCtD
